A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

Abstract Background The objectives of this study were to build upon previously-reported 12-month findings by retrospectively comparing 24-month follow-up hospitalization charges and potentially-relevant readmissions in US lumbar fusion surgeries that employed either recombinant human bone morphogene...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bradley Wetzell, Julie B. McLean, Kimberly Dorsch, Mark A. Moore
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Cellular bone allograft CBA Economics Lumbar fusion Infuse Recombinant human bone morphogenetic protein-2 Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/d826b565be034d27911084479b6ada76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d826b565be034d27911084479b6ada76
record_format	dspace
spelling	oai:doaj.org-article:d826b565be034d27911084479b6ada762021-11-21T12:30:04ZA 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)10.1186/s13018-021-02829-01749-799Xhttps://doaj.org/article/d826b565be034d27911084479b6ada762021-11-01T00:00:00Zhttps://doi.org/10.1186/s13018-021-02829-0https://doaj.org/toc/1749-799XAbstract Background The objectives of this study were to build upon previously-reported 12-month findings by retrospectively comparing 24-month follow-up hospitalization charges and potentially-relevant readmissions in US lumbar fusion surgeries that employed either recombinant human bone morphogenetic protein-2 (rhBMP-2) or a cellular bone allograft comprised of viable lineage-committed bone cells (V-CBA) via a nationwide healthcare system database. Methods A total of 16,172 patients underwent lumbar fusion surgery using V-CBA or rhBMP-2 in the original study, of whom 3,792 patients (23.4%) were identified in the current study with all-cause readmissions during the 24-month follow-up period. Confounding baseline patient, procedure, and hospital characteristics found in the original study were used to adjust multivariate regression models comparing differences in 24-month follow-up hospitalization charges (in 2020 US dollars) and lengths of stay (LOS; in days) between the groups. Differences in potentially-relevant follow-up readmissions were also compared, and all analyses were repeated in the subset of patients who only received treatment at a single level of the spine. Results The adjusted cumulative mean 24-month follow-up hospitalization charges in the full cohort were significantly lower in the V-CBA group ($99,087) versus the rhBMP-2 group ($124,389; P < 0.0001), and this pattern remained in the single-level cohort (V-CBA = $104,906 vs rhBMP-2 = $125,311; P = 0.0006). There were no differences between groups in adjusted cumulative mean LOS in either cohort. Differences in the rates of follow-up readmissions aligned with baseline comorbidities originally reported for the initial procedure. Subsequent lumbar fusion rates were significantly lower for V-CBA patients in the full cohort (10.12% vs 12.00%; P = 0.0002) and similar between groups in the single-level cohort, in spite of V-CBA patients having significantly higher rates of baseline comorbidities that could negatively impact clinical outcomes, including bony fusion. Conclusions The results of this study suggest that use of V-CBA for lumbar fusion surgeries performed in the US is associated with substantially lower 24-month follow-up hospitalization charges versus rhBMP-2, with both exhibiting similar rates of subsequent lumbar fusion procedures and potentially-relevant readmissions.Bradley WetzellJulie B. McLeanKimberly DorschMark A. MooreBMCarticleCellular bone allograftCBAEconomicsLumbar fusionInfuseRecombinant human bone morphogenetic protein-2Orthopedic surgeryRD701-811Diseases of the musculoskeletal systemRC925-935ENJournal of Orthopaedic Surgery and Research, Vol 16, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cellular bone allograft CBA Economics Lumbar fusion Infuse Recombinant human bone morphogenetic protein-2 Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935
spellingShingle	Cellular bone allograft CBA Economics Lumbar fusion Infuse Recombinant human bone morphogenetic protein-2 Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935 Bradley Wetzell Julie B. McLean Kimberly Dorsch Mark A. Moore A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
description	Abstract Background The objectives of this study were to build upon previously-reported 12-month findings by retrospectively comparing 24-month follow-up hospitalization charges and potentially-relevant readmissions in US lumbar fusion surgeries that employed either recombinant human bone morphogenetic protein-2 (rhBMP-2) or a cellular bone allograft comprised of viable lineage-committed bone cells (V-CBA) via a nationwide healthcare system database. Methods A total of 16,172 patients underwent lumbar fusion surgery using V-CBA or rhBMP-2 in the original study, of whom 3,792 patients (23.4%) were identified in the current study with all-cause readmissions during the 24-month follow-up period. Confounding baseline patient, procedure, and hospital characteristics found in the original study were used to adjust multivariate regression models comparing differences in 24-month follow-up hospitalization charges (in 2020 US dollars) and lengths of stay (LOS; in days) between the groups. Differences in potentially-relevant follow-up readmissions were also compared, and all analyses were repeated in the subset of patients who only received treatment at a single level of the spine. Results The adjusted cumulative mean 24-month follow-up hospitalization charges in the full cohort were significantly lower in the V-CBA group ($99,087) versus the rhBMP-2 group ($124,389; P < 0.0001), and this pattern remained in the single-level cohort (V-CBA = $104,906 vs rhBMP-2 = $125,311; P = 0.0006). There were no differences between groups in adjusted cumulative mean LOS in either cohort. Differences in the rates of follow-up readmissions aligned with baseline comorbidities originally reported for the initial procedure. Subsequent lumbar fusion rates were significantly lower for V-CBA patients in the full cohort (10.12% vs 12.00%; P = 0.0002) and similar between groups in the single-level cohort, in spite of V-CBA patients having significantly higher rates of baseline comorbidities that could negatively impact clinical outcomes, including bony fusion. Conclusions The results of this study suggest that use of V-CBA for lumbar fusion surgeries performed in the US is associated with substantially lower 24-month follow-up hospitalization charges versus rhBMP-2, with both exhibiting similar rates of subsequent lumbar fusion procedures and potentially-relevant readmissions.
format	article
author	Bradley Wetzell Julie B. McLean Kimberly Dorsch Mark A. Moore
author_facet	Bradley Wetzell Julie B. McLean Kimberly Dorsch Mark A. Moore
author_sort	Bradley Wetzell
title	A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
title_short	A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
title_full	A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
title_fullStr	A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
title_full_unstemmed	A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)
title_sort	24-month retrospective update: follow-up hospitalization charges and readmissions in us lumbar fusion surgeries using a cellular bone allograft (cba) versus recombinant human bone morphogenetic protein-2 (rhbmp-2)
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d826b565be034d27911084479b6ada76
work_keys_str_mv	AT bradleywetzell a24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT juliebmclean a24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT kimberlydorsch a24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT markamoore a24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT bradleywetzell 24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT juliebmclean 24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT kimberlydorsch 24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2 AT markamoore 24monthretrospectiveupdatefollowuphospitalizationchargesandreadmissionsinuslumbarfusionsurgeriesusingacellularboneallograftcbaversusrecombinanthumanbonemorphogeneticprotein2rhbmp2
_version_	1718418973834346496

A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

Ejemplares similares